Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study

Anne M. Murray, Yelena Slinin, David E. Tupper, Sarah L. Pederson, Cynthia Davey, David T. Gilbertson, Paul Drawz, Ryan Mello, Allyson Hart, Kirsten L. Johansen, Scott Reule, Rebecca Rossom, David S. Knopman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

INTRODUCTION: The associations of kidney-metabolic biomarkers with cognitive impairment (CI) beyond the estimated glomerular filtration rate (eGFR, in mL/min/1.73 m2) and albuminuria levels are not well understood. In exploratory analysis, our objective was to determine the extent that three kidney-metabolic factors, previously proposed as mechanisms of CI and commonly abnormal in chronic kidney disease (CKD), were associated with prevalent CI in CKD participants, adjusted for kidney function measures.

METHODS: The study cohort included community-dwelling individuals aged ≥45 years with CKD (eGFR <60), not requiring dialysis, recruited from four health systems. We examined the serum biomarkers bicarbonate (CO2), TNFαR1, and cholesterol as primary exposures. A structured neuropsychological battery conducted by trained staff measured global and domain-specific cognitive performance. Logistic regression analyses estimated the cross-sectional associations between kidney-metabolic measures and global and cognitive domain-specific moderate/severe (Mod/Sev) CI, adjusted for the eGFR, urinary albumin-creatinine ratio (UACR, mg/g), demographics, comorbid conditions, and other kidney-metabolic biomarkers commonly abnormal in CKD.

RESULTS: Among 436 CKD participants with mean age 70 years, 16% were Black, the mean eGFR was 34, and the median [IQR] UACR was 49 [0.0, 378] mg/g. In adjusted models, increased TNFαR1 was associated with global Mod/Sev CI (odds ratio [95% confidence interval] = 1.40 [1.02, 1.93]; p = 0.04); low bicarbonate (CO2 <20 mEq/L) with Mod/Sev memory impairment (3.04 [1.09, 8.47]; p = 0.03), and each 10-mg/dL lower cholesterol was associated with Mod/Sev executive function/processing speed impairment (1.12 [1.02, 1.23]; p = 0.02). However, after adjustment for multiple comparisons, these associations were no longer significant nor were any other kidney-metabolic factors significant for any CI classification.

CONCLUSION: In exploratory analyses in a CKD population, three kidney-metabolic factors were associated with CI, but after adjustment for multiple comparisons, were no longer significant. Future studies in larger CKD populations are needed to assess these potential risk factors for CI.

Original languageEnglish (US)
Pages (from-to)435-445
Number of pages11
JournalAmerican Journal of Nephrology
Volume53
Issue number6
DOIs
StatePublished - Jul 1 2022

Bibliographical note

Funding Information:
Dr. Anne M. Murray has been a consultant to Alkahest, Inc. Dr. David S. Knopman serves on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Third Rock, and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. All other authors list no disclosures.

Funding Information:
Funding for this work was provided by National Institute on Aging Grants #R01AG03755 and 1R01AG058729, Satellite Health Inc., Hennepin Healthcare Research Institute, and the University of Minnesota Medical Foundation.

Publisher Copyright:
© 2022 S. Karger AG, Basel

Keywords

  • Acidosis
  • Chronic kidney disease
  • Cognitive impairment
  • Inflammation
  • Risk factors

Fingerprint

Dive into the research topics of 'Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study'. Together they form a unique fingerprint.

Cite this